Zoetis Inc. (ZTS) Stock Price & Analysis
Zoetis Inc. (ZTS) rose 4.29% to USD 82.2 as of June 9, 2026 at 22:37 UTC, according to Nexqual real-time market data.
ZTS last closed at USD 78.82; the session ranged USD 79.46–82.32 on volume of 6,781,243 shares. Market capitalization is $34.46B, with a 52-week range of USD 72.38–168.83 (NYQ). Source: Nexqual, June 9, 2026 at 22:37 UTC.
Key Statistics (as of June 9, 2026 at 22:37 UTC)
| Price | USD 82.2 |
|---|---|
| Change | ▲ 4.29% (up) |
| Previous Close | USD 78.82 |
| Open | USD 79.51 |
| Day Range | USD 79.46 – 82.32 |
| 52-Week Range | USD 72.38 – 168.83 |
| Volume | 6,781,243 shares |
| Market Cap | $34.46B |
| Exchange | NYQ |
Technical Analysis (ZTS)
Nexqual's technical model rates ZTS "SELL" based on 1 bullish and 5 bearish signals across 124 daily candles, as of June 9, 2026 at 22:37 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 38.42 (neutral) |
| vs SMA50 | Below (USD 99.68) |
| MACD | -5.42 (negative) |
Analyst Ratings (ZTS)
Wall Street analysts rate ZTS "Buy" based on 17 analysts, with a mean price target of USD 124.59 (range USD 90–160), per Nexqual as of June 9, 2026 at 22:37 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 17 |
| Mean Target | USD 124.59 |
| High Target | USD 160 |
| Low Target | USD 90 |
| Buy / Hold / Sell | 11 / 9 / 0 |
Earnings (ZTS)
| Next Earnings Date | 2026-08-04 |
|---|---|
| EPS Estimate | USD 1.86 |
| Revenue Estimate | $2.51B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 1.53 vs est 1.62 ▼ miss |
| 2025-12-31 | USD 1.48 vs est 1.4 ▲ beat |
| 2025-09-30 | USD 1.7 vs est 1.62 ▲ beat |
| 2025-06-30 | USD 1.76 vs est 1.61 ▲ beat |
Source: Nexqual, June 9, 2026 at 22:37 UTC.
Financials & Fundamentals (ZTS)
| Total Revenue | $9.53B |
|---|---|
| Revenue Growth (YoY) | +2.90% |
| Gross Margin | +71.84% |
| Operating Margin | +36.56% |
| Profit Margin | +28.04% |
| ROE | +67.75% |
| Debt / Equity | 286.24 |
| Current Ratio | 3.15 |
| Total Cash | $1.94B |
| Total Debt | $9.25B |
| Free Cash Flow | $1.78B |
Source: Nexqual, June 9, 2026 at 22:37 UTC.
Financial Health Score (ZTS)
Nexqual rates Zoetis Inc.'s overall financial health "Solid" across five dimensions, as of June 9, 2026 at 22:37 UTC.
| Growth | Mixed — Revenue +2.3% YoY (annual), slow |
|---|---|
| Profitability | Strong — Gross margin 72%, operating 37% |
| Balance Sheet | Weak — $1.94B cash vs $9.25B debt |
| Cash Flow | Strong — FCF $1.78B, 19% margin |
| Efficiency | Strong — ROE 68%, ROA 15.5% |
Ownership (ZTS)
| Insider Ownership | +0.15% |
|---|---|
| Institutional Ownership | +102.92% |
| Shares Outstanding | 419.23M |
| Float | 418.38M |
| Short % of Float | +3.60% |
Source: Nexqual, June 9, 2026 at 22:37 UTC.
Leadership (ZTS)
Zoetis Inc. is led by Kristin C. Peck (age 54), CEO & Director, per Nexqual as of June 9, 2026 at 22:37 UTC.
| CEO & Director | Kristin C. Peck (age 54) |
|---|---|
| Executive VP & CFO | Wetteny N. Joseph (age 53) |
| Vice President of Investor Relations | Steven Frank |
| Executive VP and President of Global Manufacturing & Supply | Nick Ashton (age 51) |
Major Backers & Investors (ZTS)
Notable institutional backers of Zoetis Inc. include State Farm Mutual Automobile Insurance Co, Morgan Stanley, Wellington Management, according to Nexqual as of June 9, 2026 at 22:37 UTC.
Active Investors
| Investor | Stake |
|---|---|
| State Farm Mutual Automobile Insurance Co | 3.79% |
| Morgan Stanley | 3.37% |
| Wellington Management | 2.42% |
| Nordea Investment Management AB | 1.4% |
| Fidelity | 1.29% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 22.09% |
| BlackRock | 9.79% |
| State Street | 5.81% |
| Geode Capital | 2.71% |
| Northern Trust | 1.32% |
Source: Nexqual, June 9, 2026 at 22:37 UTC.
From Zoetis Inc.'s Latest SEC 10-K Filing (filed 2026-02-12)
Key Strengths & Strategy (as disclosed to the SEC)
- Zoetis enhanced the portfolio of its diagnostic products with the acquisition in 2018 of Abaxis, Inc. (Abaxis), a leading provider of veterinary point-of-care diagnostic instruments, including the Vetscan ® portfolio of benchtop and handheld diagnostic instruments and consumables.
Partnerships
- In 2024, the company started a collaboration with Blacksmith Medicines to discover and develop novel antibiotics for animal health and provide new options for our customers to treat life-threatening infections in livestock.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| IDXX | IDEXX Laboratories, Inc. | USD 578.89 | ▲ 2.98% |
| TMO | Thermo Fisher Scientific Inc | USD 494.07 | ▲ 4.5% |
| DHR | Danaher Corporation | USD 188.41 | ▲ 2.23% |
| SPGI | S&P Global Inc. | USD 424.82 | ▲ 0.09% |
| EW | Edwards Lifesciences Corporatio | USD 87.54 | ▲ 1.84% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 22:37 UTC. This page is informational and not investment advice.